Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases

NCT01781026 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

2

Enrollment

OTHER

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Vemurafenib

Sponsor

Yale University

Collaborators

[object Object]